Proliferative responses to the B-cell mitogen lipopolysaccharide (LPS; Sigma) and T-cell mitogen concanavalin A (Con-A, Sigma) were determined using MTTtetrazolium (Sigma). Splenocytes were incubated in the presence of LPS (100 pg/ml) or Con-A (16 pg/ml) at 370C in a fully humidified 5% CO2 atmosphere. At 72 hr, we added MTT-tetrazolium to all wells and incubated the cells an additional 4.5 hr. We added 10% SDS-0.01 N HCl to each well and incubated the plates overnight at 37°C. The plates were then read in a microtiter plate reader at 600 nm.
Cell-free supernatants were obtained from lymphocytes stimulated with either Con-A or LPS. After 48 hr (Con-A) or 72 hr (LPS), cells were centrifuged at 1500 rpm for 20 min, and cell-free supernatants were collected. Supernatants were frozen at -70°C until used in ELISAs.
Antibody assays were conducted using serum samples and supernatant samples from LPS-stimulated splenocytes. IgG 0-10°C. After washing and blocking, standards/samples were added and incubated overnight at 0-10°C. After washing, plates were incubated with biotinylated murine anti-IL-6 (Pharmingen). Plates were washed again and incubated with avidinperoxidase. After subsequent washing, ABTS substrate (Sigma) was added. The color reaction was stopped with sodium dodecyl sulfate in N,N-dimethylformamide and read in a microtiter plate reader at 405 nm.
Data were analyzed by ANOVA followed by the Dunnett's t -test for multiple comparisons (18) . Statistical significance was accepted at the p < 0.05 level.
Results
Mice were immunized with saline, MBP or lead-altered MBP (MBP/Pb) and anti-MBP antibodies were detected by ELISA in serum or cell-free supernatant of LPSstimulated splenocytes 10 days after the last immunization. Anti-MBP titers detected in the sera of these mice are shown in Figure 1 . Mice treated with lead-altered MBP had sera anti-MBP IgG titers that were significantly different from both control (p = 0.01) and native Proliferative responses to both Con-A and LPS mitogens were determined using the MTT assay. As shown in Figure 3 , mice immunized with lead-altered MBP exhibited significant increases in Con-Ainduced T-cell proliferation (p = 0.01) as compared to control. A significant increase was not seen in mice immunized with native MBP. There were no treatmentrelated increases in LPS-induced B-cell proliferation in any group.
Levels of IL-2 and IL-6 were quantified in supernatants of lectin-stimulated splenocytes. Mice immunized with leadaltered MBP exhibited increased IL-6 levels that were significantly different from control (p = 0.05). However, the levels of IL-2 produced by stimulated splenocytes Volume 102, Number 12, December 1994from these animals were not different from control values (Fig. 4) .
Immunizations were also conducted with another lead-altered neural protein, GFAP. The treatment protocol used for GFAP differed from that used for MBP in that a group of mice exposed to PbOAc alone was added. This was done because recovery of lead-altered GFAP from the Sephadex columns was poor. GFAPimmunized mice exhibited responses in the sera that were analogous to those observed in the sera of MBP-immunized mice. Mice immunized with lead-altered GFAP showed sera anti-GFAP IgG titers that were statistically different from control (p = 0.01), lead alone (p = 0.01) and native GFAP-immunized mice (p = 0.05). There were no elevated titers of anti-GFAP IgM in the sera (Fig. 5) .
Lectin-stimulated supernatants from GFAP-immunized mice were also analyzed for the production of anti-GFAP antibodies and for IL-2 and IL-6 levels. The only observed changes occurred in mice treated with native GFAP. These animals exhibited supernatant anti-GFAP IgG titers that were significantly different from controls (p = 0.01). Mice immunized with lead-altered GFAP did not show an increase in anti-GFAP IgG titers. In addition, there were no increases in anti-GFAP IgM titers in any group (Fig. 6 ). Stimulated splenocytes taken from mice treated with lead-altered GFAP showed no increases in either IL-2 or IL-6 production (Fig. 4) . The lymphoproliferation assays showed no increases in the proliferation of splenocytes stimulated with either Con-A or LPS (data not shown).
Serum antibodies did not react with keratin for any of the animals in any group, confirming that the ELISA reactions were target specific (data not shown).
Discussion
The present study shows that lead enhances the immunogenicity of two nervous system proteins, MBP and GFAP. These results support our hypothesis that the progression of lead-induced neurotoxicity may be due to the production of autoantibodies against neural proteins provoked by a lead-induced enhancement of the immunogenicity of those proteins. These results also complement our earlier work showing that lead exposure induces autoantibody titers against nervous system proteins, including MBP and GFAP (11,1X. Usually, the first immmunoglobulin to occur after initial antigen contact is IgM (13) . In many T-cell independent responses, IgM remains the primary immunoglobulin. However, isotype switching to IgG occurs during T-dependent immune responses (13) . In this study, enhanced IgG antibody titers were seen in the sera, whereas IgM titers in the sera were unchanged from control values. This indirect evidence suggests a T-cell dependent response for the generation of antibodies against both lead-altered MBP and GFAP.
MBP is a negatively charged 18 kDa protein of approximately 170 amino acid residues (19. It is distinctive for its lack of sulfhydryl groups (19) . In contrast, GFAP is a positively charged 52 kDa protein which contains methionine and cysteine groups (20) . These differences between the proteins suggest that lead may be binding and altering the immunogenicity of each in a different manner. The lead ion carries a double positive charge and may bind to MBP in a charge neutralization process. Because of the double positive charge, it is also possible for lead to cross-link between negative charges on two different MBP molecules making the lead-altered form more immunogenic in this manner. In contrast, because GFAP is positively charged but contains sulfhydryl groups, it is possible that lead is binding to a methionine or cysteine residue and perhaps unmasking an epitope, making the leadaltered form of GFAP more immunogenic. These potential differences in the way lead binds to MBP and GFAP may produce different types of antigenic determinants on the two lead-altered proteins causing antibodies to be generated against the two lead-altered proteins through different mechanisms. The observed differences between the responses generated by the lead-altered forms of MBP and GFAP in the supernatants of lectin-stimulated splenocytes provide evidence for this proposition. In the splenic supernatants, Con-Ainduced proliferation was increased in mice treated with lead-altered MBP (Fig. 3) but not with lead-altered GFAP (data not shown). Further, there was a significant increase in IL-6 production by LPS-stimulated splenocytes of mice immunized with lead-altered MBP but not with lead-altered GFAP (Fig. 4) . In addition, anti-MBP IgG antibody titers were elevated in the supernatants of LPS-stimulated splenocytes of mice immunized with lead-altered MBP, but an analogous response was not seen in the splenocyte supernatants of mice immunized with lead-altered GFAP (Figs. 2 and  6 ). Since there is indirect evidence that both lead-altered proteins induce antibody production through T-cell-dependent mechanisms, the splenic supernatant responses suggest that different subsets of T-helper cells may be involved in the generation of antibodies by the two different lead-altered proteins.
It is known that immunization with protein antigens leads to the activation of different types of helper T-cells: Thl and Th2 (14) . Th2 cells are considered optimal helpers for B-cell responses, while Thl cells are not considered efficient helpers (17) . These two subtypes differentially regulate immune responses via the cytokines they secrete. Thl cells secrete IL-2 and inteferon-g, whereas Th2 cells secrete IL-4, -5, -6, and -10 (21). Of these cytokines, IL-2 and IL-6 were selected for analyses in the present studies because they stimulate antibody secretion by B-cells (22) . Our evidence suggests that lead-altered MBP activates different cytokine-secreting cells from lead-altered GFAP, as elevated IL-6 levels were found in the splenic supernatants of lead-altered MBP-treated mice but not in the supernatants of lead-altered GFAP-treated mice.
Because the present study demonstrates that lead enhances the immunogenicity of two neural proteins, it raises the possibility that lead, and perhaps other metals, may be involved in the pathogenesis of immunologically mediated neurological diseases. Several of these diseases manifest autoantibodies to neural proteins at some stage of the disorder. For example, in both humans and experimental animals, MBP is the target antigen for immune processes leading to autoimmune encephalomyelitis (23) . Autoantibodies against MBP as well as GFAP have been found in the cerebrospinal fluid (CSF) of multiple sclerosis patients (24, 25) . In addition, stimulated B-cells from the CSF of multiple sclerosis patients produce antibodies against MBP (26) . Autoantibodies against MBP and GFAP are also observed in other disorders. For example, increased anti-MBP titers are seen in patients with subacute sclerosing panencephalitis and post-infectious encephalomyelitis (27) . Patients with Lyme neuroborreliosis also exhibit elevated CSF anti-MBP titers (28) . Autoantibodies against MBP as well as against GFAP are seen in the serum of patients with Alzheimer's disease (29) (30) (31) . Although Alzheimer's disease primarily affects neurons, there is secondary involvement of myelin; therefore, humoral immune reactions to MBP might develop as the disease progresses (29) . In addition, GFAP has been shown to stimulate proliferation and immunoglobulin synthesis by lymphocytes from patients with Alzheimer's disease (4). Serum anti-GFAP autoantibodies are seen in patients suffering from senile dementias and in healthy, aging people (32) . Because of the presence of autoantibodies against nervous system proteins in several neurological disorders and because of the suspected involvement of environmental pollutants in the pathogenesis of neurological diseases, it is reasonable to propose a mechanism whereby metal alteration of neural proteins leads to autoantibody production against neural structures, causing progressive degeneration of the nervous system.
Finally, it should be pointed out that autoantibodies against neural proteins have the potential to serve as early biomarkers of impending neurological disease because they may appear before traditional pathological manifestations. If our hypothesis is correct and metals induce or intensify immune responses against neural structures, neurotypic autoantibodies have the potential to act as early and sensitive biomarkers for the effects of neurotoxic metals. Studies concerned with the timing of metal-induced neurotoxicity versus the timing of the appearance of neurotypic antibodies would address this question and will be the subject of a fiture report.
